See Total Prescribing Facts OPDIVO® (nivolumab) is indicated with the treatment of adult patients with classical Hodgkin lymphoma (cHL) which has relapsed or progressed following autologous hematopoietic stem mobile transplantation (HSCT) and brentuximab vedotin or after three or more traces of systemic therapy that includes autologous HSCT.It cou